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Studies have reported human bocavirus (HBoV) in chil-
dren with respiratory tract infections (RTIs), but only occa-
sionally in adults. We searched for HBoV DNA in nasopha-
ryngeal aspirates (NPAs) from adults with exacerbations of 
chronic bronchitis or pneumonia, from children hospitalized 
for acute RTIs, and from asymptomatic children during the 
winter of 2002–2003 in Canada. HBoV was detected in 
NPAs of 1 (0.8%) of 126 symptomatic adults, 31 (13.8%) of 
225 symptomatic children, and 43 (43%) of 100 asymptom-
atic children undergoing elective surgery. Another virus was 
detected in 22 (71%) of the 31 HBoV-positive NPAs from 
symptomatic children. Two clades of HBoV were identiﬁ  ed. 
The pathogenic role of HBoV in RTIs is uncertain because 
it was frequently detected in symptomatic and asymptom-
atic children  and was commonly found with other viruses in 
symptomatic children.
H
uman bocavirus (HBoV) is a newly described human 
virus closely related to bovine parvovirus and canine 
minute virus. It is currently classiﬁ  ed in the genus Bocavirus 
within the family Parvoviridae. This virus was ﬁ  rst identi-
ﬁ  ed in respiratory tract specimens from Swedish children 
with lower respiratory tract infections (RTIs) (1). Nucleic 
acid ampliﬁ  cation has detected  HBoV in respiratory sam-
ples of children with acute respiratory disease, with inci-
dence rates ranging from 3% to 19% (1–23). However, the 
pathogenic role of HBoV is uncertain because other viruses 
have been frequently detected in HBoV-positive children 
with lower RTIs (range 37%–90%) (2,3,7,9–11,20–22). 
The objective of this study was to describe the incidence 
and clinical manifestations of HBoV infections in children 
and adults with respiratory tract symptoms, including a 
control group of children without symptoms.
Materials and Methods
Study Design
Respiratory samples from adults were obtained from 
a previous study conducted from December 2002 to April 
2003 at 3 university-afﬁ  liated hospitals in the province of 
Quebec, Canada (24). Two groups of patients were enrolled: 
those >40 years of age with chronic obstructive pulmonary 
disease (COPD) who came to emergency departments with 
exacerbation of their illness (including patients with pneu-
monia), and those >18 years of age without COPD who 
were admitted to the hospital with a diagnosis of commu-
nity-acquired pneumonia. Patients were excluded from the 
study if they came to the hospital >7 days after onset of 
symptoms. 
Respiratory samples from children were obtained from 
a case-control study, the results of which have been pub-
lished (25). Participants included children <3 years of age 
who were hospitalized from December 2002 to April 2003, 
at Laval University Hospital Center in Quebec City, Que-
bec, Canada. Case-patients were children admitted for an 
acute RTI (mostly bronchiolitis, pneumonitis, and laryn-
gotracheobronchitis) who had a nasopharyngeal aspirate 
(NPA) collected as part of investigation of their illness. 
A speciﬁ  c questionnaire was completed at admission by a 
research nurse in the presence of the parents. At the end 
of hospitalization, charts of the children were reviewed 
to collect clinical and laboratory data. Eligible controls 
were children hospitalized during the same period for any 
elective surgery (ear, nose, and throat surgeries in 71% of 
the cases). These children had no concomitant respiratory 
symptoms or fever at admission. The study nurse obtained 
a signed consent from parents and an NPA was obtained 
during surgery. The original studies were reviewed and ap-
proved by the ethics committees of all participating health-
care centers.
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Laboratory Testing
All pediatric (from case-patients and controls) and 
adult (case-patients only) NPA specimens were previously 
analyzed by using a multiplex real-time PCR assay for in-
ﬂ  uenza A and B viruses, human respiratory syncytial virus 
(hRSV), and human metapneumovirus (hMPV) (24,25). 
For symptomatic children, viral cultures and antigen detec-
tion assays were performed upon request by the treating 
physician. Remaining specimens were frozen at –80°C un-
til subsequent HBoV PCR studies.
Nucleic acids were extracted from 200 μL of NPA by 
using the QIAamp viral RNA Mini Kit (QIAGEN, Inc., Mis-
sissauga, Ontario, Canada). A duplex HBoV PCR (TaqMan 
assay) was used to amplify conserved regions of NP-1 and 
NS-1 genes as described (14), except that the NS-1 forward 
primer was replaced with primer 5′-TAG TTG TTT GGT 
GGG ARG A-3′. Probes were labeled with 6-carboxyﬂ  uo-
rescein (FAM) or tetrachloro-6-carboxyﬂ  uorescein  (TET) 
at the 5′ end and with a quencher at the 3′ end. Amplicons 
were 81 bp (NP-1) and 74 bp (NS-1), respectively. Duplex 
ampliﬁ  cation was conducted by using 1 μmol/L NS-1 for-
ward primer and 0.4 μmol/L NS-1 reverse primer and the 2 
NP-1 primers. Taqman probes were used at concentrations 
of 0.1 mmol/L for the NP-1 gene and 0.2 mmol/L for the 
NS-1 gene (14). The ampliﬁ  cation master mixture consisted 
of 2.5 mmol/L MgCl2, 3.33 mg/mL bovine serum albumin, 
0.2 mmol/L of each of the 4 deoxynucleotide triphosphates 
(Amersham Biosciences, Uppsala, Sweden), 10 mmol/L 
Tris-HCl, 50 mmol/L KCl, 0.625 U Promega Taq DNA 
polymerase (Fisher Scientiﬁ  c, Markham, Ontario, Canada) 
combined with TaqStart antibody (BD Biosciences Clon-
tech, Palo Alto, CA, USA), and 3 μL DNA in a ﬁ  nal volume 
of 25 μL. PCR ampliﬁ  cation (180 s at 94°C and 45 cycles for 
10 s at 95°C, 30 s at 58°C, and 30 s at 72°C) was performed 
in a Smart Cycler thermal cycler (Cepheid, Sunnyvale, CA, 
USA). A PCR extension step of 5 min at 72°C was performed 
at the end of the cycling protocol. An HBoV infection was 
deﬁ  ned by a positive PCR result for NP-1 and NS-1. The 
duplex assay had a sensitivity of 10 genome copies for NP-1 
and NS-1 gene targets on the basis of quantiﬁ  cation analysis 
of positive control plasmids. 
Half of the HBoV-positive samples were randomly 
selected for phylogenetic analysis, which consisted of am-
plifying and sequencing a 842-bp region of the VP1/VP2 
genes as described (6). The VP1/VP2 nucleotide sequences 
from this study, as well as prototype sequence type (ST)1 
and ST2 (1), were entered into a multiple alignment gen-
erated by ClustalW software version 1.83 (www.molecu-
larevolution.org/software/clustalw) and corrected through 
ﬁ  nal visual inspection with the SeqLab application (Wis-
consin package version 10.3; Accelrys, San Diego, CA, 
USA). Phylogenetic analyses were conducted with the 
MEGA version 3.1 software (26) by using the distance 
method and the neighbor-joining algorithm with Kimura-2 
parameters. Topologic accuracy of the tree was evaluated 
by using 1,000 bootstrap replicates.
Statistical Analysis
Proportions of clinical characteristics in different 
groups of patients were compared by using the χ2 test or 
the Fisher exact test. The Wilcoxon nonparametric test was 
used to compare age distribution and length of stay. Anal-
yses were performed by using SAS software version 9.1 
(SAS Institute, Inc., Cary, NC, USA).
Results
HBoV DNA was detected in NPA samples from 1 
(0.8%) of 126 symptomatic adults (71 years of age) and 
from 31 (13.8%) of 225 symptomatic children (mean age 
17 months, median age 15 months). However, HBoV was 
detected more frequently (43%, p<0.001) in the 100 as-
ymptomatic control children (mean age 22 months, median 
age 23 months). Another virus was detected in 22 (71%) of 
31 HBoV-positive NPAs from symptomatic children. The 
virus most commonly co-isolated with HBoV was hRSV 
(16/31, 52%), followed by inﬂ  uenza A/B (3 cases), hMPV 
(3 cases), adenovirus (1 case), and parainﬂ  uenza virus (1 
case). Two children were infected with 2 other viruses in 
addition to HBoV. The median age of symptomatic chil-
dren with HBoV infection (15 months) was signiﬁ  cantly 
greater than that of symptomatic children without HBoV 
infection (8 months; p<0.0001). The hospital length of stay 
was similar for children positive for HBoV DNA (mean 5.1 
days, median 4 days) and those negative for HBoV DNA 
(mean 6.6 days, median 3 days) (p = 0.9).
Clinical characteristics of HBoV-positive children are 
summarized in the Table. There were signiﬁ  cantly fewer 
bronchiolitis episodes in children infected only with HBoV 
than in children infected only with hRSV (p<0.0001). None 
of the children with single HBoV infections and only 2 
(6%) of all 31 HBoV-infected children were admitted to 
the intensive care unit. In the control group of asymptomat-
ic children who underwent elective surgery, ear, nose, and 
throat surgery was more frequently performed in children 
with HBoV infections (36/43, 84%) than in children with-
out HBoV infections (35/57, 61%) (p = 0.014). Ear, nose, 
and throat elective surgeries consisted mainly of myringot-
omies, adenoidectomies, and tonsillectomies.
The 1 adult with an HBoV infection was a 71-year-old 
man (a smoker) who came to the hospital for a COPD exac-
erbation and was treated with systemic corticosteroids and 
antimicrobial drugs. No other microbiologic agents (bacte-
ria or viruses) could be identiﬁ  ed in his sputum or NPA. He 
was hospitalized for 11 days.
Sequence analysis of the HBoV VP1/VP2 genes per-
formed on ≈50% of HBoV-positive specimens showed 2 
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distinct clades of viruses (Figure). These genotypes clus-
tered with the original strains described by Allander et al. 
(ST1, GenBank accession no. DQ000495, and ST2, Gen-
Bank accession no. DQ000496) (1). There was no temporal 
link between the clades because both were equally distrib-
uted throughout the study period. No obvious relationship 
was found between clades and the presence or absence of 
symptoms.
Discussion
Results from our study indicate that HBoV was rarely 
detected in adults with respiratory symptoms but was fre-
quently detected in symptomatic and asymptomatic chil-
dren during the 2002–2003 winter season. HBoV was de-
tected in NPA samples from 1 (0.8%) of 126 symptomatic 
adults, 31 (13.8%) of 225 symptomatic children, and 43 
(43%) of 100 asymptomatic children. Another virus was 
detected in 22 (71%) of 31 HBoV-positive samples from 
symptomatic children. Overall, these data do not support a 
pathogenic role for HBoV in acute RTIs in children.
The full spectrum of clinical diseases associated with 
HBoV infections and the epidemiology of this new parvo-
virus are not fully understood. This is particularly true for 
adult patients in whom few studies have been performed. 
Allander et al. (1) found no HBoV DNA in 112 culture-
negative NPA samples from adults with respiratory symp-
toms. Bastien et al. (5) reported an overall rate of infection 
of 1.5% in respiratory samples negative for other viruses, 
with no differences between age groups. Maggi et al. (16) 
reported only 1 HBoV-positive sample from an adult with 
lymphoma in 62 bronchoalveolar lavages (BALs). These 
investigators also tested 22 nasal swabs from adults with 
persistent asthma symptoms and found no samples posi-
tive for HBoV. Fry et al. (10) identiﬁ  ed HBoV DNA in 1% 
of adults >20 years of age hospitalized with pneumonia in 
Thailand. Kupfer et al. (27) described a case of HBoV in-
fection associated with severe atypical pneumonia in a pa-
tient with non-Hodgkin lymphoma who was also infected 
with cytomegalovirus in a BAL sample. We found 1 case 
of HBoV infection in an adult, which represented 0.8% of 
the tested population. The HBoV-positive adult did not 
show immunosuppression but was treated with cortico-
steroids for a COPD exacerbation. Overall, our results are 
consistent with those of previously described studies and 
support the fact that HBoV infection is rare in adults but 
may occur more frequently in those with other illnesses or 
immunosuppression.
Studies have reported HBoV DNA in 3%–19% of 
children with RTIs. Rates of detection tend to be higher 
in children <1 year of age (4,10). The incidence of HBoV 
infections also tends to be higher in samples from the 
lower respiratory tract, such as NPA or BAL (4.4%–19%) 
(2,7,9,11,13,19,21,22), than in nasal swabs (1%–6%) 
(10,15,16,18). The percentage of co-pathogens in our 
HBoV-positive children (71%) was comparable with those 
reported in the literature, with rates of co-infections rang-
ing from 35% to 90% (2,3,7,9–11,20–22). Moreover, co-
infecting viruses detected in conjunction with HBoV in our 
population were similar to those described in other studies, 
i.e., hRSV, inﬂ  uenza A virus, and adenovirus (11,23).
The high frequency of HBoV detection (43%) in our 
asymptomatic children contrasts with the results of the few 
other studies that included a control group of asymptomatic 
children. Fry et al. (10) detected HBoV DNA in only 1% of 
nasal swabs from asymptomatic patients. Maggi et al. (16) 
did not detect HBoV DNA in nasal swabs from 51 asymp-
tomatic children (including 30 healthy infants with a mean 
age of 6 months and 21 preadolescent healthy children with 
a mean age of 12.8 years). However, these studies analyzed 
nasal swabs instead of NPA or BAL samples for HBoV 
detection, which may result in lower rates of viral detec-
tion, as shown in symptomatic persons. Allander et al. (2) 
did not detect HBoV in any of 64 asymptomatic children 
(median age 4.1 years, range 5 months to 14 years) but used 
nasal swabs in asymptomatic patients and NPA samples in 
symptomatic patients. Furthermore, their control group was 
also older than our population (mean 18.6 months, median 
18 months). Kesebir et al. (12) did not detect any HBoV 
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(n = 31) 
HBoV, single 
infections
(n = 9) 
hRSV, single 
infections
(n = 97) 
hMPV, single 
infections
(n = 12) 
Influenza A/B virus, 
single infections  
(n = 3) 
Pneumonia, no. (%)  13 (42)  4 (44)  17 (18)  1 (8)  1 (33) 
Bronchiolitis, no. (%)†  13 (42)  1 (11)  83 (86)  5 (42)  2 (67) 
Laryngotracheobronchitis, no. (%)  0 0 0 0 0
Otitis media, no. (%)  19 (61)  4 (44)  58 (60)  7 (58)  1 (33) 
Median (mean) length of stay, d  3 (6.6)  3 (3.6)  4 (4.6)  3 (6.7)  4 (4.0) 
Admission to ICU, no. (%)  2 (6)  0 10 (10)  0 0
Underlying cardiopulmonary disorders, 
no. (%)‡ 
3 (10)  0 11 (11)  3 (25)  3 (100) 
Prematurity, no. (%)  2 (6)  0 10 (10)  0 0
*HBoV, human bocavirus; hRSV, human respiratory syncytial virus; hMPV, human metapneumovirus; ICU, intensive care unit. 
†p<0.0001 for  comparison of single infections. 
‡p = 0.0014 for comparison of single infections. RESEARCH
DNA in nasal washes from 96 asymptomatic children <2 
years of age seen at a clinic compared with 22 (5.2%) of 
425 various samples from symptomatic children sent to a 
hospital clinical laboratory. None of the previous studies 
used a control group consisting of children matched for age 
and week of admission and analyzed the same type of re-
spiratory samples for cases and controls.
Our positive results for HBoV were conﬁ  rmed by us-
ing 2 sets of PCR primers targeting different genes (NP1 
and NS1) in a duplex PCR assay and by subsequent testing 
with a third set of primers (VP1/VP2) for sequencing. Also, 
sample preparation and PCR ampliﬁ  cation were performed 
in separate laboratory areas following the stringent quality 
control program of our institution. Thus, it is unlikely that 
our positive results were due to PCR cross-contamination. 
Our method was also very sensitive (detection limit = 10 
genome copies), which probably enabled an increased in-
fection rate compared with previous reports. We cannot ex-
clude the possibility that prior RTIs (in the few weeks pre-
ceding sampling) occurred in our asymptomatic children 
hospitalized for an elective surgery or that HBoV could 
establish a prolonged infection in children compared with 
other respiratory viruses. However, the 3× higher detection 
rate in controls than in symptomatic children make these 
explanations unlikely. We did not quantify HBoV DNA 
load in samples from our study, which could have been dif-
ferent between asymptomatic and symptomatic children. 
Nevertheless, we detected hRSV, hMPV, and inﬂ  uenza 
virus RNA in <1% of the same NPA samples from those 
asymptomatic children compared with a rate of 43% for 
HBoV DNA (25). At the very least, our results should raise 
concerns about the pathogenic role of HBoV in children.
We detected 2 HBoV genotypes circulating at the same 
time in both symptomatic and asymptomatic children dur-
ing the winter of 2002–2003 in Quebec. This result is con-
sistent with ﬁ  ndings of other groups from North America 
and Europe during 2002–2004 and highlights the fact that 
HBoV lineages do not appear to be geographically clus-
tered (1,6,9,12). The seasonality of HBoV infection is still 
a matter of debate, but it seems to involve primarily the 
colder months of the year (9,20,21). However, most stud-
ies, including ours, were performed during the typical re-
spiratory virus season, which may have introduced a bias. 
Additional studies are needed to address the prevalence of 
HBoV outside the respiratory virus season and its role in 
nonrespiratory syndromes. Moreover, the possibility that 
this virus might be transmitted and isolated in the respira-
tory tract, but could cause viremia and other clinical syn-
dromes such as gastroenteritis, should be investigated. Vi-
cente et al. analyzed 527 stool samples from children with 
gastroenteritis and no respiratory symptoms and found a 
positivity rate of 9.1% for HBoV (with a co-infection rate 
of 58%) (22).
In conclusion, our study shows that HBoV was fre-
quently detected in both symptomatic and asymptomatic 
children during the winter of 2002–2003 in Quebec City. 
Conversely, this virus was rarely found in the adult popu-
lation during the same period. Further studies are needed 
to establish whether this recently described parvovirus is 
pathogenic by using well-matched control groups and se-
quential samples to detect viral persistence.
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Figure. Phylogenetic tree of human pediatric bocavirus strains 
from Quebec City, Quebec, Canada. Patient numbers beginning 
with the letter t indicate asymptomatic (control) children. Strains 
from Sweden (sequence type [ST] 1, GenBank accession no. 
DQ000495, and ST2, GenBank accession no. DQ000496) are 
included (1). Numbers along branches are bootstrap values from 
1,000 replicates. Scale bar shows 1 substitution for every 1,000 
nucleic acid residues.Human Bocavirus Infections
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